Tiny skin study aims to unlock secrets of psoriasis drug
NCT ID NCT07244744
First seen Nov 24, 2025 · Last updated May 09, 2026 · Updated 26 times
Summary
This study looks at how the drug tildrakizumab helps people with moderate to severe plaque psoriasis. Researchers will take small skin samples from three patients before and after treatment to see how immune cells change. The goal is to understand why the drug works and how long its effects last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CCIM, Institut für Entzündungsmedizin UKSH Lübeck
Lübeck, <Keine Auswahl>, 23562, Germany
Conditions
Explore the condition pages connected to this study.